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Abstract 
Background: Malaria is endemic in Tanzania with majority of clinical cases caused by Plasmodium falciparum. 
Additionally, Plasmodium malariae and Plasmodium ovale spp. are also present and clinical manifestations caused by 
these infections are not well described. Clinical episodes caused by P. malariae infections are often characterized by 
a relatively mild illness with a low number of parasites, which can persist for long periods. In this report, two cases of 
P. malariae infections that were identified during a clinical trial evaluating the P. falciparum malaria vaccine candidate, 
PfSPZ Vaccine are described. The two participants were followed up and monitored for clinical and laboratory param-
eters to assess vaccine safety providing the opportunity to study clinical manifestations of P. malariae over 4 months.
Case presentation: Two young, healthy Tanzanian men infected with low density asexual blood stage P. malariae 
diagnosed by quantitative polymerase chain reaction (qPCR) are described. Retrospective analysis of collected and 
stored blood samples revealed that the two volunteers had constant asexual blood stage parasitaemia for more than 
4 months. During the 132 days of infection, the volunteers’ vital signs, body temperature and serum biochemistry all 
remained within normal ranges. Haematological abnormalities, which were transiently outside normal ranges, were 
regarded as not clinically significant. During this time period, four consecutive evaluations of blood samples by thick 
blood smear microscopy conducted by an experienced microscopist were all negative, indicating the presence of 
low-density sub-microscopic infections.
Conclusions: The two cases of P. malariae infections presented here confirm the ability of this Plasmodium species to 
persist at low density in the human host for extended time periods without causing clinical symptoms. The presented 
data also demonstrate that clinical study sites in malaria endemic regions need to have a strong malaria diagnostic 
infrastructure, including the ability of capturing sub-microscopic parasitaemia and differentiation of Plasmodium 
species.
Trial registration ClinicalTrials.gov: NCT02613520, https ://clini caltr ials.gov/ct2/show/NCT02 61352 0, Registered: Novem-
ber 24th 2015, Enrolment of the first participant to the trial: December 15th 2015, Trial was registered before the first 
participant was enrolled
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Background
Malaria is endemic in Tanzania with more than 90% of 
the population at risk and 5.6 million cases reported by 
the public health sector in 2017 [1]. While Plasmodium 
falciparum is the dominant malaria species responsible 
for majority of infections and deaths, other Plasmodium 
species are also endemic in Tanzania. David Clyde, who 
served as the director of the Malaria Service of the East 
African Malaria Institute at Amani, described the occur-
rence of four human malaria  species, including P. falci-
parum, Plasmodium vivax, Plasmodium ovale spp. and 
Plasmodium malariae in his 1967 book “Malaria in Tan-
zania” [2]. Plasmodium vivax was attributed to importa-
tion by Indian immigrants during the first world war and 
since 1917 this influx has virtually ceased. Plasmodium 
malariae was observed in 10–20% of malaria infections, 
mainly as co-infections with  P. falciparum and during 
childhood [2]. More recently, a microscopy-based cross-
sectional survey conducted in the Tanga region of coastal 
Tanzania found very few infections with P. malariae 
(0.3%) or P. ovale spp. (0.1%) [3]. Data collected in coastal 
Tanzania, confirm these low numbers of non-P. falcipa-
rum Plasmodium infections. Diagnosis by qPCR revealed 
low prevalence for P. malariae (0.7–5.8%) and P. ovale 
spp. (0.9–1.1%) among asymptomatic school children 
(Schindler et  al., unpublished data). Since microscopic 
diagnosis of P. malariae asexual blood stage parasites is 
hampered by the low parasitaemia and morphological 
similarities to P. falciparum, molecular based, highly sen-
sitive diagnostic methods are needed to establish the true 
prevalence of this parasite in the population [4]. Lack of 
sensitive P. malariae diagnosis methods applicable in the 
field and the research focus on P. falciparum has resulted 
in significant knowledge gaps regarding spectrum of 
potential clinical manifestations and burden of P. malar-
iae infections [5].
It is well established that P. malariae is widespread 
throughout sub-Saharan Africa, South East Asia and 
Latin America and the biology of P. malariae was 
reviewed by Collins et  al. [6]. Treatment of syphilis by 
controlled infections with P. malariae provided valu-
able insight into human-parasite interactions. The red 
blood cell cycle lasts 72 h with an average of 8 merozoites 
released per schizont and the parasite prefers to infect 
and develop in older erythrocytes. So far, no evidence for 
a dormant liver stage as described in P. vivax and P. ovale 
spp. has been observed. Faster acquisition of immu-
nity against P. malariae compared to immune responses 
against P. falciparum has been described [6].
Clinical episodes of P. malariae infections are charac-
terized by a mild illness caused by low numbers of para-
sites which can persist for extremely long periods, often 
for years or even decades [6]. There are reports of cases 
of P. malariae caused illness from Greece [7] and Trini-
dad and Tobago [8] decades after eradication of malaria 
from these regions. Chronic P. malariae  infections have 
been considered a major cause of the nephrotic syn-
drome in the past, although the incidence of P. malaria-
associated nephrotic syndrome has been dramatically 
reduced in recent decades [7–9]. Recently, it was dem-
onstrated that the controlled infection of two volunteers 
with cryopreserved P. malariae-infected erythrocytes 
was well tolerated and no severe or serious adverse effect, 
or biochemical abnormalities were observed [10].
The clinical research facility of the Ifakara Health 
Institute in Bagamoyo, Tanzania, conducts clinical tri-
als evaluating efficacy of experimental malaria vaccines 
in the target population [11–13]. A controlled human 
malaria infection (CHMI) model has been successfully 
established since 2012 [14]. As part of these clinical trials, 
participants are closely monitored to identify any abnor-
mal clinical or laboratory parameters in order to evaluate 
vaccine safety and tolerability. Regularly, volunteers are 
screened for Plasmodium spp. parasites in blood using 
thick blood smear microscopy as well as quantitative pol-
ymerase chain reaction (qPCR). The volunteers described 
in this report participated in a study evaluating the safety 
and efficacy of immunization with  Sanaria® PfSPZ Vac-
cine composed of radiation attenuated, aseptic, purified, 
cryopreserved P. falciparum sporozoites (PfSPZ) [11, 
15–19] which was conducted between 2015 and 2016 
(clinicaltrials.gov: NCT02613520) [20]. The clinical cases 
of two young men infected with asexual blood stage P. 
malariae as diagnosed by qPCR are described. These 
volunteers were followed closely for 4 months during the 
clinical trial.
Case presentation
Two male residents of Bagamoyo, 20 and 22 years of age, 
were enrolled into the clinical trial based on predefined 
exclusion and inclusion criteria as outlined in the clinical 
trial protocol. A review of the medical history, physical 
examination, vital signs (pulse, blood pressure, and res-
piratory rate), and ECG did not reveal any abnormalities. 
At screening, the volunteers had negative serologies for 
human immunodeficiency virus (HIV), hepatitis B virus 
(HBV), and hepatitis C virus (HCV). A single stool sam-
ple collected at study enrolment was negative for intes-
tinal helminths and no Schistosoma haematobium eggs 
were detected in urine. No blood biochemistry abnor-
malities were detected, which included alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), 
total bilirubin (BIL), and creatinine (CRE). The urine 
analysis using a 13-parameter dipstick (Combina 13 
test strips, HUMAN Diagnostics, Germany) was nega-
tive at enrolment. A complete blood count (CBC) was 
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conducted at screening and showed normal haematologi-
cal parameters for volunteer 1, while volunteer 2 had ele-
vated eosinophil counts (1.19 × 103/µL compared to the 
pre-defined upper normal range of 0.78 × 103 cells/µL). 
During the 16 weeks of immunization (3 doses of PfSPZ 
Vaccine at 8-week intervals), the volunteers’ health sta-
tus was closely monitored. Every 8 weeks at pre-defined 
visits blood was drawn and any deviations from refer-
ence laboratory values were reported. Vital signs, body 
temperature and biochemistry remained within normal 
ranges when assessed four times during the follow up 
period. Haematological parameters which were tran-
siently outside normal ranges in both volunteers were 
regarded as not clinically significant (Tables 1, 2). Note-
worthy, for volunteer 2 the eosinophil counts remained 
consistently elevated until the end of the study (Fig.  1). 
Both volunteers tested once positive for low grade pro-
teinuria, during the study by urine dipstick (Tables 1, 2).  
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Fig. 1 Elevated eosinophil counts for volunteer 2 over a time period 
of more than 400 days. Eosinophil counts of volunteer 2 covering all 
visits, from study enrolment to completion, are shown. The dashed 
line represents the upper limit of the normal range (0.78 × 103 cells/
µL)
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Fig. 2 qPCR data for the Plasmodium spp. screening and Plasmodium species identification assays. The upper panel shows the amplification curves 
for the Plasmodium spp. target of the screening assay. The lower panel shows the amplification for the four Plasmodium species-specific targets. All 
samples were run in triplicates and DNA from P. falciparum, P. malariae, P. ovale wallikeri, P. ovale curtisi and P. vivax were included as positive controls 
during the qPCR
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After concluding three PfSPZ Vaccine immunizations, 
and before vaccine efficacy was assessed by CHMI, the 
study protocol required screening of whole blood by 
qPCR to detect sub-microscopic malaria parasitaemia, 
so that these volunteers could be treated accordingly 
before participation in CHMI. During this routine visit, 
qPCR was conducted with fresh blood samples and it 
was discovered that two volunteers were infected with 
Plasmodium spp. parasites [21]. Based on P. malariae 
species-specific qPCR [22] and conventional nested PCR 
[23], P. malariae infections were confirmed. The presence 
of P. falciparum [24, 25], P. ovale spp. [26], and P. vivax 
[25] was excluded by qPCR and conventional PCR [23].
Treatment with 3 doses of artesunate/amodiaquine 
(200/540 mg) daily for 3 days was initiated, and complete 
parasite clearance was confirmed by qPCR 4  days later. 
Both volunteers then underwent CHMI and remained in 
the clinical trial until study completion. Within the fol-
lowing 296 days until the completion of the clinical trial, 
no recurrent (recrudescence or new infection) P. malar-
iae parasitaemia was observed. Both volunteers were 
negative for P. falciparum after the first CHMI, and both 
became positive for P. falciparum after a second CHMI at 
40 weeks after the last immunization and were success-
fully treated with artemether/lumefantrine.
Blood samples collected during the clinical trial and 
stored frozen were analysed retrospectively by qPCR 
to determine the time point of P. malariae infection. It 
turned out that both volunteers had P. malariae para-
sitaemia at enrolment into the clinical trial. Both vol-
unteers remained positive throughout the vaccination 
period. Plasmodium malariae parasites were detectable 
at four out of four clinical visits, namely at day 0, 53, 
113 and 128 of study and malaria treatment took place 
132 days after the first detection of the P. malariae infec-
tions (Fig. 2). Evaluation of four blood samples collected 
at the same days by thick blood smear microscopy and 
conducted by an experienced microscopist was reported 
as negative. Thick blood smear preparation and reading 
was performed according to our standard operating pro-
cedure followed during CHMI studies [14]. The negative 
microscopy results and the high Cq values (median of 
34.1 with a range of 31.6–37.7) obtained by the Plasmo-
dium spp. qPCR assay indicate that the parasitaemia lev-
els were low. When compared to qPCR based detection 
of P. falciparum 18S gene, these Cq values would corre-
spond to a parasitaemia between 1 and 10 P. malariae 
parasites per µL blood [27].
Discussion and conclusion
The two P. malariae cases presented here confirm the 
ability of this Plasmodium species to persist at low den-
sity in the human host for extended time periods without 
causing clinical symptoms or signs. Both were detected 
in clinically healthy, young men participating in a clini-
cal trial of PfSPZ Vaccine. No abnormalities in vital 
signs, alanine aminotransferase, aspartate aminotrans-
ferase, total bilirubin, and creatinine serum levels were 
detected. Except for a one-time low-level proteinuria, 
urine analysis parameters measured by dipstick remained 
within physiological ranges and there was no indica-
tion of impaired renal function in these two volunteers. 
Volunteer 2 did have mildly elevated eosinophil counts 
throughout the entire course of the clinical trial. These 
levels were not affected by the treatment of the P. malar-
iae infection and may have reflected an ongoing intesti-
nal helminth infection that was too low to be detected 
by a single stool examination. All other haematological 
abnormalities were of temporary nature and considered 
to be not clinically significant. Interestingly, the P. malar-
iae parasitaemia levels were not affected by the three 
rounds of PfSPZ Vaccine immunizations. This might be 
due the mode-of-action of the vaccine which is thought 
to act against the liver-stage of the parasite.
The data presented in this report demonstrates that 
study sites in malaria endemic regions conducting clini-
cal trials should develop on site malaria diagnostic infra-
structure, which includes the detection of low-density 
asexual blood stage parasitaemia and identification of 
different Plasmodium species. Eventually, if the goal of 
malaria elimination is pursued vigorously, the implemen-
tation of highly sensitive diagnostic methods to detect 
asymptomatic, low-density P. malariae infections need to 
be included into the malaria elimination agenda.
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